BrightPath Biotherapeutics Co., Ltd.
4594.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.13 | 0.54 | 0.17 |
| FCF Yield | -34.90% | -27.50% | -11.75% | -28.56% |
| EV / EBITDA | -2.44 | -2.82 | -5.95 | -2.17 |
| Quality | ||||
| ROIC | -114.68% | -100.45% | -90.40% | -55.29% |
| Gross Margin | 97.18% | -473.61% | 64.11% | 78.47% |
| Cash Conversion Ratio | 1.09 | 0.99 | 0.81 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.13% | -83.28% | 28.23% | 10.89% |
| Free Cash Flow Growth | -7.48% | 3.45% | 21.15% | 15.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.68 | 0.81 | 1.04 | 1.53 |
| Interest Coverage | 0.00 | -825.65 | -24,050.15 | -4,077.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 20,437.35 | 12.74 | -11.03 | 182.51 |